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Abstract  41 
Background – According to 2016 WHO/UNICEF country estimates Eritrea has overall high 42 
vaccination coverage with immunisation rates for 3 doses of diphtheria/tetanus/pertussis and polio 43 
vaccine of 95%, for 2 doses measles vaccine of 85%, and for 3 doses Hepatitis B vaccine of 85%. If 44 
confirmed, this could imply that routine basic vaccination of newly arrived Eritreans could be safely 45 
omitted.  46 
Methods – We used stored serum samples from two cross-sectional studies that screened newly 47 
arrived Eritrean refugees for infectious diseases. Consenting refugees aged 16 years and older who 48 
registered in one of three neighbouring cantons in northwestern Switzerland were enrolled between 49 
January 2016 and December 2017. Antibody titers against the following vaccine-preventable diseases 50 
were measured (applied thresholds for seroprotection in brackets): diphtheria (> 0.1 IU/ml), tetanus (> 51 
0.1 IU/ml), measles (> 150 mIU/ml), rubella (only for women,> 11 IU/ml), varicella (> 50 mIU/ml), 52 
hepatitis B (HbsAg Index > 0.9, antiHBc Index > 0.9 and antiHBs > 10 IE/L). Differences between 53 
sex and age groups (≤ 25 and >25 years) were measured by Fisher’s exact test.  54 
Results – We analysed samples of 133 study participants (20 women, 15%) with a median age of 55 
25 years (range 16-61). Rates of sero-positivity were as follow for women / men respectively: 56 
diphtheria 57.9% / 74.8% (difference non significant), tetanus 94.8% / 41.1% (p<0.001), measles 57 
73.7% / 76.6% (non sig.), rubella in women 78.9%, varicella 89.5% / 95.3% (non sig.), anti-HBc 58 
15.8% / 26.2% (non sig.), and anti-HBs 15.8% / 17.8% (non sig.) 59 
Conclusion – Sero-prevalence for vaccine-preventable infections did not meet levels required to 60 
confer herd-immunity in any of the human-to-human transmissible diseases that were studied. In 61 
general, the strategy proposed by the Federal Office of Public Health to offer basic immunization to all 62 
newly arrived refugees, including newly arriving Eritrean refugees, is justified. 63 
 64 
Key words 65 
Eritrea; asylum seekers; vaccine-preventable diseases; migrants; herd immunity; vaccination 66 
coverage  67 
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Background 68 
In 2015 and 2016, humanitarian crises in the Middle and Far East as well as in the horn of 69 
Africa lead to a large wave of migrants seeking asylum in Europe. In most countries of origin, 70 
the public health system had seriously deteriorated, if not completely collapsed. Hence, 71 
vaccination coverage was expected to be markedly lower than in previous periods. In refugee 72 
camps the en route provision of primary health care, including immunization, relied heavily 73 
on the presence of non-governmental organisations and was impeded. Studies in newly 74 
arrived asylum seekers in Germany1-3 showed seropositivity rates of various vaccine-75 
preventable diseases (VPD) well below those known to confer herd immunity.  76 
Hence, many countries receiving refugees issued blanket recommendations to offer primary 77 
immunization4-7 to newly arriving refugees, irrespective of age. In Switzerland, all newly 78 
arrived asylum seekers are informed on access to screening for infectious diseases and are 79 
offered care and vaccination in federal registration centres (FRC). Recommendations to 80 
provide age-specific basic immunization to children and catch-up immunization to adults 81 
exist.8 However, vaccination was explicitly delegated to primary health care physicians at the 82 
community level once the formal process of registration was finalized, i.e. often after several 83 
months. Adherence to this recommendation is not known, but likely to be low. Due to 84 
repeated outbreaks of varicella and cases of cutaneous diphtheria in asylum seekers, from 85 
2018 onward, the recommendation has changed to start a full course of age-specific basic 86 
immunization early after arrival at the FRC level.  87 
Eritreans account for the largest group of asylum seekers in Switzerland9 (18.7% of all newly 88 
registered asylum seekers in 2017). The Expanded Program of Immunization (EPI) in Eritrea 89 
was launched in 1980, initially including vaccines against diphtheria, pertussis, tetanus, 90 
poliomyelitis, measles and tuberculosis. However, noticeable progress in program 91 
implementation was only seen after independence in 1991. Hepatitis B was introduced in 92 
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2002 and the pentavalent vaccine combining the vaccines against diphtheria, pertussis, 93 
tetanus, hepatitis B and Haemophilus influenzae type b was introduced in 2008.  94 
According to data from the World Health Organisation and UNICEF (WHO/UNICEF), 95 
Eritrea is among one of the countries with very high vaccine coverage rates.10 With reference  96 
to 2016 WHO/UNICEF data, Eritrea had a 95% coverage for the completion of three doses of 97 
diphtheria/tetanus/pertussis and polio (DTP3 and Pol3), 93% for at least one dose of a measles 98 
containing vaccine and 95% for the 3rd dose of hepatitis B containing vaccine following the 99 
birth dose. Data from an EPI coverage survey in the year 2000 among children 0-23 months 100 
showed only marginally lower coverage rates: DPT3/OPV3 coverage was 93.6%, and measles 101 
coverage (one dose) was 82.5%. These are very high coverage rates, higher than in some 102 
European countries. Consequently, young Eritrean asylum seekers may not need to be fully 103 
re-immunised upon arrival in Europe. This would save unnecessary vaccine doses at the 104 
individual as well as at public health levels. Our objective was to assess the percentage of 105 
newly arrived Eritrean asylum seekers with protective antibody titers for six VPDs. Studies on 106 
VPDs among newly arrived asylum seekers in other European countries included mainly 107 
participants from the WHO Eastern Mediterranean Region (EMRO), namely from Syria, Iran, 108 
Iraq and Afghanistan, and only few Eritreans were included. To our knowledge, this is the 109 
largest sample assessing immune responses against multiple VPDs in Eritreans.  110 
 111 
Methods  112 
We used stored serum samples from two cross-sectional studies that screened newly arrived 113 
(<12 months since entry) Eritrean asylum seekers for infectious diseases. Both studies were 114 
conducted in three neighbouring cantons in northwestern Switzerland. Recruitment and 115 
sampling methods have been published previously.11,12 Samples were obtained between 116 
January 11th 2016 and December 27th 2017. Ethics approval was granted from the regional 117 
ethics committee (EKNZ 2015-353/PB_2017-00092 Amendment 3 & 4 and EKNZ 2016-118 
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00005). We enrolled consenting refugees aged ≥16 years (Cantons Basel-Stadt and -Land) or 119 
aged ≥15 (Canton Solothurn).  We did not ask for vaccination history, as we could not verify 120 
this information as it is highly unlikely for this population to arrive with a vaccination card. 121 
Antibody titers against the following VPD were measured (applied thresholds for sero-122 
protection in brackets): diphtheria (> 0.1 IU/ml), tetanus (> 0.1 IU/ml), measles (> 150 123 
mIU/ml), rubella (only for women, > 11 IU/ml), varicella (> 50 mIU/ml), hepatitis B (HBsAg 124 
Index > 0.9, anti-HBc Index > 0.9 and anti-HBs > 10 IE/L).  125 
Sample preparation and analysis 126 
Blood samples were collected in serum tubes and centrifuged at 2000g for 5 min after 127 
complete coagulation at room temperature. After separation, the serum was frozen in aliquots 128 
at minus 20°C until performance of serological tests. Rubella virus IgG and hepatitis B virus 129 
(HBs Antigen qualitative, anti-HBc total Ig, anti-HBs IgG were analysed on an Architect® 130 
system (Abbott, Chicago, USA), a fully automated immune-analyser based on 131 
chemiluminescent microparticle immunoassays (CMIAs). IgG antibodies against measles and 132 
varicella virus were determined using Serion ELISA classic measles Virus IgG kit and 133 
varicella zoster virus IgG, respectively (Virion/Serion GmbH, Würzburg, Germany) 134 
according to the manufacturer’s instruction. IgG diphtheria and IgG tetanus antibodies were 135 
detected by VaccZyme diphtheria toxoid IgG ELISA and VaccZyme tetanus toxoid IgG 136 
ELISA from Binding site (Birmingham, UK). 137 
Results are presented as median titers and interquartile ranges (IQR), and percentage of the 138 
participants with a titer above the indicated threshold for sero-protection. Fisher’s exact test 139 
was used to detect differences between sex and age groups (≤ 25 and > 25 years of age). 140 
These two age groups correspond to about half of the participant population but they also 141 
represent those born before and after 1991, the year of Eritrean independence and when EPI 142 
implementation started to progress. 143 
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All serological analyses were performed at the Institute for Infectious Diseases, University of 144 
Bern.  145 
Results 146 
We included 133 Eritrean asylum seekers with a median age of 25 years (range 16-61), 47.4% 147 
were ≤ 25 years old, and 98.5% were below the age of 45 years. Women made up 15% (n=20) 148 
of all participants.  149 
The distribution of disease-specific sero-prevalence is presented in table 1, table 2 and figure 150 
1. There was no difference in sero-protection rates between the sexes except for tetanus, 151 
where 18 (95%) out of 19 women had a positive titer compared to 44 (41%) out of 107 men 152 
(p<0.001). In the age group above 25 years, 36% had positive antibodies against the Hepatitis 153 
B core antigen (anti-HBc) compared to 11% in those younger than 25 years (p=0.001). 154 
Similarly, in the older age group 23% had antibodies against Hepatitis B surface antigen (anti-155 
HBs) compared to 11% in the younger group (trend, p= 0.097). In the whole population 156 
69.9% remained susceptible for Hepatitis B infection and would qualify for vaccination. For 157 
the other diseases, there was no difference between the two age groups, though point 158 
estimates indicated a trend towards higher sero-prevalence in those older than 25 years (data 159 
not shown). 160 
Discussion  161 
In newly arrived Eritrean asylum seekers, we found overall lower rates of sero-positivity for 162 
VPDs than anticipated - given the WHO/UNICEF immunization coverage figures for Eritrea 163 
in 2016.10 Sero-prevalence in this population failed to reach the threshold expected to confer 164 
herd immunity against measles and rubella (≥ 95%13) and against diphtheria and varicella 165 
(80% and 91% respectively14). The implications are that this population remains vulnerable to 166 
primary infection with these diseases after arrival in Switzerland.  167 
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Our study shows lower rates of sero-positivity for measles, rubella, and varicella than other 168 
European studies among newly arrived asylum seekers in the same period. A study from 169 
Germany reported an overall IgG sero-positivity of 88.5% for measles, 77.9% for rubella and 170 
95.9% for varicella.2 However, the majority of participants in that study (83%) were from the 171 
WHO Eastern Mediterranean Region (EMRO) and only 4.6% from African regions. Another 172 
study in the Netherlands showed a relatively high overall sero-protection rate in 622 173 
participants: 88% for measles, 94% for rubella and 96% for varicella.3 Again, most study 174 
participants were from EMRO, and only 9% (n=56) were from Eritrea. An Italian study15, 175 
including 134 Eritreans, found 79.9% positive measles antibodies in this population, this is 176 
closer to the rate reported in our study (76.2%).  177 
Furthermore, regarding diphtheria and tetanus, the latter study found high overall sero-178 
protection rates of 82% and 98% respectively.3 Eritreans, however, were the exception, with a 179 
markedly lower tetanus sero-prevalence of 41%. Another study conducted in Germany1 180 
(without mention of country of origin of asylum seekers) found similarly low levels of sero-181 
protection, stating that only 43.7% and 23.9% had sufficient tetanus respectively diphtheria 182 
IgG levels that corresponded to long-term protection. Our study corresponds to these results: 183 
only 68.4% of both sexes showed to have a positive titer for diphtheria and only 41.1% of 184 
men had a positive titer for tetanus. However, women showed a surprisingly high percentage 185 
with positive tetanus titers (95%), most probably indicating that they had received booster 186 
doses in pregnancies (as recommended by the WHO).  187 
Nearly one quarter of the study participants showed positive Hepatitis B core antibodies (anti-188 
HBc), as a marker of past or current infection with Hepatitis B. However, only 1.5% had a 189 
positive HBs-antigen, indicative of chronic infection. This implies that most participants had 190 
experienced functional cure with loss of HBs-antigen. This result goes in line with data from 191 
general estimates for Eritrea16, which classify it as one of only three countries in the African 192 
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region with a prevalence of positive HBs-antigen of < 5%. Immunity to Hepatitis B, as 193 
measured by positive Hepatitis B surface antibodies (anti-HBs), was only found in 16.5% of 194 
the participants.  195 
One of the strengths of this study is that it provides data for the largest asylum seeker 196 
population in Switzerland, for whom so far data has been lacking. Furthermore, age 197 
distribution of the study population is similar to the data provided by the federal asylum 198 
seekers statistics,9 allowing us to assume that our data are representative for the population of 199 
Eritrean asylum seekers.  200 
The limitations of our study lie in the moderate sample size and the low number of female 201 
participants (15%). In addition, only humoral antibody response was measured, and follow-up 202 
antibody titers in response to booster doses to assess cellular memory function was not 203 
measured. Hence, boostable cellular immunity to these diseases may be underestimated.  204 
In summary, we found insufficient levels of sero-protection for all measured VPDs in this 205 
population, leaving them vulnerable to primary infection within Switzerland. The 206 
recommendation to offer basic immunization to all newly arrived asylum seekers in 207 
Switzerland appears justified, also for persons originating from Eritrea.   208 
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Table 1 – Serology results of Diphtheria, Tetanus, Measles, Rubella and Varicella 270 
 reference  
medi
an 
titer  
(IQR
) 
positi
ve*  
% (n) 
weak
ly 
posit
ive  
% (n) 
border
line  
% (n) 
negat
ive  
% (n) 
missi
ng  
% 
(n)& 
p-
valu
e%  
men 
vs. 
wom
en 
Diphth
eria 
IgG 
[IU/ml] 
positive >0.1  
all 
0.17 
(0.10 
– 
0.44) 
68.4% 
(91) 
na na 
26.3
% 
(35) 
5.3% 
(7) 
 
wom
en 
 
57.9% 
(11) 
42.1
% (8) 
0.17 
men 
74.8% 
(80) 
25.2
% 
(27) 
Tetanu
s IgG 
[IU/ml] 
positive >0.1 
all 
0.09 
(0.07 
– 
0.48) 
46.6% 
(62) 
na na 
48.1
% 
(64) 
5.3% 
(7) 
 
wom
en 
 94.8% 
(18) 
5.3% 
(1) 
<0.0
01 
men 
41.1% 
(44) 
58.9
% 
(63) 
Measle
s IgG 
[mIU/m
l] 
negative <150  
borderline ≥150-200  
positive >200  
 
all 
639 
(205 
– 
1465
76.2% 
(96) 
na 
4.0% 
(5) 
19.8
% 
(25) 
5.3% 
(7) 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/jtm
/advance-article-abstract/doi/10.1093/jtm
/taz035/5486058 by ISTM
 M
em
ber Access user on 18 July 2019
14 
 
 
 
) 
wom
en 
 73.7% 
(14) 
5.3% 
(1) 
21.0
% (4) 
0.8 
men 
76.6% 
(82) 
3.7% 
(4) 
19.6
% 
(21) 
Measle
s IgG 
[mIU/m
l], if 
border
line to 
positiv
e 
negative <150 
positive ≥150 
 
all 
639 
(205 
– 
1465
) 
75.9% 
(101) 
na na 
18.8
% 
(25) 
5.3% 
(7) 
 
wom
en 
 
78.9% 
(15) 
21.0
% (4) 
1.0 
men 
80.4% 
(86) 
19.6
% 
(21) 
Rubell
a IgG 
[IU/ml], 
only 
women
, n=20 
(15%) 
negative <5 
borderline ≥5-10 
positive >10 
wom
en 
29.8 
(21.6 
– 
73.3) 
78.9% 
(15) 
na 
5.3% 
(1) 
15.8
% (3) 
5% 
(1) 
n.a. 
VZV 
IgG 
[mIU/m
l] 
negative <50 
weakly positive ≥50-
100  
positive >100  
 
all 
473 
(222 
– 
849) 
87.2% 
(116) 
2.3% 
(3) 
na 
5.3% 
(7) 
5.3% 
(7) 
 
wom
en  
84.2% 
(16) 
5.3% 
(1) 
10.5
%  (2) 0.19 
men 93.5% 1.9% 4.7% 
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(100) (2) (5) 
VZV 
IgG 
[mIU/m
l], if 
weakly 
posi-
tive to 
pos. 
negative <50 
positive ≥50  
 
all 
473 
(222 
– 
849) 
89.5% 
(119) 
na na 
5.3% 
(7) 
5.3% 
(7) 
 
wom
en 
 
89.5% 
(17) 
10.5
% (2) 
0.28 
men 
95.3% 
(102) 
4.7%  
(5) 
Abbreviations and footnotes: VZV – Varicella-Zoster virus; IU/ml – international units / millilitre; * positive indicates the 271 
percentage of participants with a titer that confers protection; & missing are always data from the same 6 men and 1 272 
woman; % Fisher’s exact test 273 
  274 
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Table 2 – Hepatitis B status among Eritrean asylum seekers 275 
 All*&, in %  
Susceptible  69.9%  
Chronic Hepatitis B 1.5%  
Immunity from previous infection  21.8%  
Immunity from vaccination  0.8% 
*p-value for difference between sexes (Fisher’s exact) for all analyses >0.5 276 
& missing values: 7 277 
Definitions 278 
- Susceptible: HBs-antigen negative | anti-HBc and anti-HBs negative 279 
- Chronic Hepatitis B: HBs-antigen positive | anti-HBc and anti-HBs negative 280 
- Immunity from previous infection: HBs-antigen negative | anti-HBc positive +/- anti-HBs 281 
- Immunity from vaccination: HBs-antigen and anti-HBc negative | anti-HBs positive 282 
 283 
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